Anti-mesothelin (msln) single domain antibodies and therapeutic constructs
AssigneeNational Research Council of Canada
InventorsMehdi ARBABI-GHAHROUDI, Scott MCCOMB, Robert PON, Risini WEERATNA
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-MSLN single domain antibodies (sdAb), as well as constructs comprising the sdAbs. The constructs include multivalent antibodies comprising any one of the sdAbs, such constructs including bispecific T-cell engagers (BiTEs), bispecific natural killer cell engagers (BiKEs), and trispecific killer cell engagers (TrikEs). Also described are chimeric antigen receptors (CARs) for CAR-T and CAR-NK therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancers (in particular, solid cancers) are also described.
Claims26
An isolated single domain antibody (sdAb), or a construct thereof comprising said sdAb, which sdAb binds specifically to human mesothelin (hMSLN), the sdAb comprising
- i) a CDR1 amino acid sequence as set forth in SEQ ID NO:
- 86, 25, 4, 22, 1, 7, 10, 13, 16, 19, 28, 31, 34, 37, 40 or 43;
- ii) a CDR2 amino acid sequence as set forth in SEQ ID NO:
- 87, 26, 5, 23, 2, 8, 11, 14, 17, 20, 29, 32, 35, 38, 41, or 44;
- and
- iii) a CDR3 amino acid sequence as set forth in SEQ ID NO:
- 88, 27, 6, 24, 3, 9, 12, 15, 18, 21, 30, 33, 36, 39, 42, or 45;
- or
- CDR1, CDR2, and CDR3 amino acid sequences that are, as a group, at least 80%, at least 85%, or at least 90% identical to the respective CDR1, CDR2, and CDR3 amino acid sequences, as a group, selected from parts i)-iii).
Dependencies are inferred from the claim text.